Hamid Soraya, Maryam Rameshrad, Aram Mokarizadeh, Alireza Garjani*
|
Alireza Sharifi*, Mohammad Charjouei Moghadam
|
Hamed Hamishehkar, Soheila Hosseini, Abdolhossein Naseri, Azam Safarnejad, Farzaneh Rasoulzadeh*
|
Ailar Nakhlband, Yadollah Omidi*
|
Alireza Farnam, Ali Fakhari, Leila Roshangar, Sajjad Kahni, Sara Farhang*
|
Seyed Esmail Razavi, Vahid Farhangmehr*, Nafiseh Zendeali
|
Cécilia Delattre*, Diego Velazquez, Caroline Roques, Graciela Pavon-Djavid, Véronique Ollivier, Anna Lokajczyk, Thierry Avramoglou, Virginie Gueguen, Liliane Louedec, Giuseppina Caligiuri, Martine Jandrot-Perrus, Catherine Boisson-Vidal, Didier Letourneur, Anne Meddahi-Pelle
Schematic illustration of the subsequent steps for the stents coating process and the evaluation of their biocompatibility: in vitro, ex vivo and in vivo (abdominal aorta stenting and stent restenosis preclinical models) evaluation of Dex-PBMA.
|
Samira Gholizadeh , Hossein Haghaei, Hosna Karami, Somaieh Soltani* , Mostafa Zakariazadeh, Javad Shokri
Interaction of the Fingolimod with HSA was studied using multi-spectroscopic and molecular modeling methods. Fingolimod binds to the binding site II of HSA via hydrogen bonds and Van der Walls forces. The binding is enthalpy driven. Fingolimod interaction with HSA leads to the conformational change of HSA.
|
Aleksandr L. Urakov* , Natalya A. Urakova, Ilnur I. Yagudin, Milena D. Svetova, Darya O. Suntsova
The purpose of this letter was to present a model for evaluating the biological activity of drugs, which can become a new vector for the development of effective ways to increase blood oxygenation across pulmonary and save the lives of patients with severe atypical pneumonia complicated by respiratory obstruction in COVID-19.
|
Jake Langlie , Ariel Finberg, Nathalie B. Bencie, Jeenu Mittal, Hossein Omidian, Yadollah Omidi , Rahul Mittal, Adrien A. Eshraghi*
Using 3D cell models to understand the etiology and molecular mechanisms underlying auditory disorders holds great potential for developing more targeted and effective novel therapeutics.
|
Farkhonde Hasannejad , Leila Montazeri, João F Mano* , Shahin Bonakdar* , Ahmad Fazilat
|
Saman Heydari , Mohammad Barzegar-Jalali, Mostafa Heydari, Afsaneh Radmehr, Ana Cláudia Paiva-Santos, Maryam Kouhsoltani, Hamed Hamishehkar*
|